Your browser version may not work well with NCBI's Web applications. More information here...
1: Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8.Click here to read Links

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.

Bruncko M, McClellan WJ, Wendt MD, Sauer DR, Geyer A, Dalton CR, Kaminski MA, Weitzberg M, Gong J, Dellaria JF, Mantei R, Zhao X, Nienaber VL, Stewart K, Klinghofer V, Bouska J, Rockway TW, Giranda VL.

Cancer Research, Global Pharmaceutical R&D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6101, USA. milan.bruncko@abbott.com

A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors.

PMID: 15582418 [PubMed - indexed for MEDLINE]

Structures reported by this article